Last reviewed · How we verify

Staphylococcal pharyngitis — Treatment Landscape & Competitive Intelligence

Staphylococcal pharyngitis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Staphylococcal pharyngitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Amoxil amoxicillin Generic (originally Beecham/GSK) Aminopenicillin (Beta-lactam antibiotic) 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C 1972-01-01
Amoxycillin Amoxycillin King George's Medical University 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C
Amoxicilli Amoxicilli Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Beecham/GSK) · 1 drug in Staphylococcal pharyngitis
  2. King George's Medical University · 1 drug in Staphylococcal pharyngitis
  3. Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · 1 drug in Staphylococcal pharyngitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Staphylococcal pharyngitis:

Cite this brief

Drug Landscape (2026). Staphylococcal pharyngitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staphylococcal-pharyngitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing